Regeneron Pharmaceuticals (NASDAQ:REGN) : Traders are bullish on Regeneron Pharmaceuticals (NASDAQ:REGN) as it has outperformed the S&P 500 by a wide margin of 0.08% in the past 4 weeks. The bullishness in the stock continues even in the near-term as the stock has returned an impressive 4.2%, relative to the S&P 500. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 5.54% in the last 1 week, and is up 1.7% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock.
The company shares have dropped -29.44% from its 1 Year high price. On Aug 4, 2015, the shares registered one year high at $605.93 and the one year low was seen on Jun 27, 2016. The 50-Day Moving Average price is $373.18 and the 200 Day Moving Average price is recorded at $404.43.
The stock has recorded a 20-day Moving Average of 5.82% and the 50-Day Moving Average is 0.88%.
Regeneron Pharmaceuticals (NASDAQ:REGN): stock turned positive on Friday. Though the stock opened at $372.6, the bulls momentum made the stock top out at $378.85 level for the day. The stock recorded a low of $370.21 and closed the trading day at $378.35, in the green by 1.86%. The total traded volume for the day was 692,888. The stock had closed at $371.45 in the previous days trading.
In an insider trading activity, Ryan Arthur F, director of Regeneron Pharmaceuticals Inc, unloaded 1,000 shares at an average price of $396.64 on May 24, 2016. The total amount of the transaction was worth $396,640, according to the disclosed information with the Securities and Exchange Commission in a Form 4 filing.
Regeneron Pharmaceuticals, Inc. is an integrated biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, colorectal cancer, and a rare inflammatory condition and has product candidates under development in other areas, including hypercholesterolemia, oncology, rheumatoid arthritis (RA), asthma and atopic dermatitis. The Companys marketed products include EYLEA (aflibercept) injection, ZALTRAP (ziv-aflibercept) injection for intravenous infusion and ARCALYST (rilonacept) injection for subcutaneous use. The Company has 17 product candidates in clinical development. Its product candidates consist of two trap-based clinical programs and 15 human monoclonal antibody product candidates. The Company has generated each of the antibodies using its VelocImmune technology.